comparemela.com

Latest Breaking News On - Meeting of the oncologic drugs advisory committee - Page 1 : comparemela.com

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Sundar-jagannath
Kennethc-anderson
Bristol-myers-squibb
Meeting-of-the-oncologic-drugs-advisory-committee
Oncologic-drugs-advisory-committee
Oncologic-drugs-advisory-committee-meeting
Johnson
Youtube
Drugs-advisory-committee
Cancer-care
Myers-squibb

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

United-states
America
Kennethc-anderson
Johnson
Oncologic-drugs-advisory-committee
Bristol-myers-squibb
Meeting-of-the-oncologic-drugs-advisory-committee
Drugs-advisory-committee
D
Dana-farber-cancer-institute
Hodac

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

New-york
United-states
Saadz-usmani
Johnson
Oncologic-drugs-advisory-committee
Janssen-biotech-inc
Meeting-of-the-oncologic-drugs-advisory-committee
Drugs-advisory-committee
Myeloma-service
Memorial-sloan-kettering-cancer-center

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

New-york
United-states
Sunil-iyer
Oncologic-drugs-advisory-committee
Meeting-of-the-oncologic-drugs-advisory-committee
Columbia-university-irving-medical-center
International-prognostic-scoring-system
Drugs-advisory-committee
Science-summit
New-york-city
D
Mds

FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.

Roche-polivy
Oncologic-drugs-advisory-committee
International-prognostic-index
Youtube
Meeting-of-the-oncologic-drugs-advisory-committee
Drugs-advisory-committee
Pacific-lymphoma-conference
Polatuzumab-vedotin-piiq
Diffuse-largeb-cell-lymphoma
Dlbcl

vimarsana © 2020. All Rights Reserved.